Medigene Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/21/2025)
| Balance Sheet | Total Assets | 10,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 8,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -500,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -14,500,000.00 | – | – |
| Cashflow | Operating Cash Flow | -14,000,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.67 | Div. Yield | – |
| Income | Net Income | -18,000,000.00 | P/E | – |
| Income | Shares Outstanding | 27,000,000.00 | P/B | – |
| Income | Total Revenue | 10,000,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.medigene.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more